BioSyent Inc. (CVE:RX - Free Report) - Research analysts at Bloom Burton lowered their FY2026 EPS estimates for shares of BioSyent in a research report issued to clients and investors on Tuesday, May 20th. Bloom Burton analyst D. Martin now expects that the company will earn $0.86 per share for the year, down from their previous estimate of $0.88. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent's FY2027 earnings at $0.93 EPS.
BioSyent Trading Up 1.7%
Shares of CVE RX traded up C$0.20 during trading hours on Wednesday, reaching C$11.95. The stock had a trading volume of 2,163 shares, compared to its average volume of 4,745. BioSyent has a 52-week low of C$8.97 and a 52-week high of C$12.13. The firm has a market cap of C$136.68 million, a price-to-earnings ratio of 19.39 and a beta of 0.93. The business's fifty day moving average price is C$10.84 and its two-hundred day moving average price is C$11.07. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
